(Total Views: 400)
Posted On: 01/05/2017 8:55:34 AM
Post# of 23059
$GNCA
06:55 AM EST, 01/05/2017 (MT Newswires) -- Genocea Biosciences (GNCA) is up more than 20% in pre-market trading after the company said its genital herpes vaccine met multiple clinical endpoints at the six-month mark.
GEN-003 significantly reduced the rate of genital lesions during the six months following dosing compared to placebo, the company said, at 4.5% of days vs. 7.9% and representing a 41% reduction. The vaccine also showed statistically significant reduction in mean lesion rate, mean duration of recurrences, mean number of recurrences over six months, the Kaplan-Meier estimate of percent recurrence free after first dose, and the Kaplan-Meier estimate of percent recurrence free after last dose.
The company said its end of Phase 2 meeting with the U.S. Food and Drug Administration is expected in Q1 and a Phase 3 trial is expected to launch in Q4.
06:55 AM EST, 01/05/2017 (MT Newswires) -- Genocea Biosciences (GNCA) is up more than 20% in pre-market trading after the company said its genital herpes vaccine met multiple clinical endpoints at the six-month mark.
GEN-003 significantly reduced the rate of genital lesions during the six months following dosing compared to placebo, the company said, at 4.5% of days vs. 7.9% and representing a 41% reduction. The vaccine also showed statistically significant reduction in mean lesion rate, mean duration of recurrences, mean number of recurrences over six months, the Kaplan-Meier estimate of percent recurrence free after first dose, and the Kaplan-Meier estimate of percent recurrence free after last dose.
The company said its end of Phase 2 meeting with the U.S. Food and Drug Administration is expected in Q1 and a Phase 3 trial is expected to launch in Q4.
(0)
(0)
Nothing I state is intended to be a recommendation to buy or sell, opinion only. Readers are solely responsible for how they use the information.
